Author + information
- Received December 10, 1990
- Revision received February 4, 1991
- Accepted February 17, 1991
- Published online August 1, 1991.
- Walter C. Brogan III, MD, PhDa,b,
- Richard A. Lange, MD, FACCa,b,
- Anatole S. Kim, MDa,b,
- David J. Moliterno, MDa,b and
- L.David Hillis, MD, FACC∗,a,b
- ↵∗Address for reprints: L. David Hills, MD, Room CS 7, 102, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75235.
Cocaine induces vasoconstriction of epicardial coronary arteries in patients with and without coronary artery disease, and this vasoconstriction is particularly marked in segments narrowed by atherosclerosis. To assess the effect of nitroglycerin on cocaine-induced coronary vasoconstriction, computer-assisted quanitative analysis was performed on nondiseased and diseased coronary artery segments in 23 patients (18 men, 5 women, aged 43 to 65 years) 1) at baseline, 2) after administration of intranasal saline solution (in 8 patients) or 2 mg/kg of cocaine (in 15 patients), and then 3) after administration of sublingual placebo (in 6 patients) or 0.4 or 0.8 mg of nitroglycerin (in 9 patients) in the 15 patients given cocaine.
In response to cocaine administration, coronary artery crosssectional area decreased 22 ± 7% (mean ± SD) in nondiseased segments (p < 0.05) and 45 ± 18% in diseased segments (p < 0.02). The magnitude of vasoconstriction was greater (p = 0.01) in the diseased segments. Sublingual nitroglycerin abolished the vasoconstriction in both nondiseased and diseased segments. Thus, nitroglycerin alleviates cocaine-induced vasoconstriction in patients with coronary artery disease.
☆ This study was supported in part by Ischemic Specialized Center of Research Grant HL-17669 from the National Institutes of Health, Bethesda, Maryland and by a grant from the Texas Affiliate of the American Heart Association, Austin, Texas.
- Received December 10, 1990.
- Revision received February 4, 1991.
- Accepted February 17, 1991.